| 英文名称 | 中文名称 | CAS |
|---|---|---|
| RKI-1313 (Negative control of RKI-1447) | 1-(3-METHOXYBENZYL)-3-(4-(PYRIDIN-4-YL)THIAZOL-2-YL)UREA | 1342276-76-9 |
| Ro 31-8220 mesylate | RO-31-8220 | 138489-18-6 |
| Ro 46-2005 | RO462005 | 150725-87-4 |
| Ro48-8071 | RO 48-8071盐 | 161582-11-2 |
| RO8994 | RO 8994 | 1309684-94-3 |
| RS-127445 | 2-氨基-4-(4-氟萘-1-基)-6-异丙基嘧啶 | 199864-87-4 |
| Ruxolitinib | 鲁索替尼 | 941678-49-5 |
| RWJ67657 | 4-(4-氟苯基)-2-(4-羟基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑 | 215303-72-3 |
| SB-202190 | 4-(4-氟苯基)-2-(4-羟基苯基)-5-(4-吡啶基)-1H-咪唑 | 152121-30-7 |
| SB-203580 | 4-(4-氟苯基)-2-(4-甲基亚磺酰基苯基)-5-(4-吡啶基)-1H-咪唑 | 152121-47-6 |
| SB-3CT | SB-3CT | 292605-14-2 |
| SB-505124 | SB-505124 | 694433-59-5 |
| SB525334 | 6-[2-(1,1-二甲基乙基)-5-(6-甲基-2-吡啶基)-1H-咪唑-4-基]喹喔啉 | 356559-20-1 |
| SB-742457 | 3-苯基磺酰基-8-(哌嗪-1-基)喹啉 | 607742-69-8 |
| SBC-115076 | sbc-115076 | 489415-96-5 |
| SBI-0206965 | SBI0206965; SBI-0206965; SBI 0206965. | 1884220-36-3 |
| SC-66 | SC 66 | 871361-88-5 |
| SC-79 | 2-氨基-6-氯-ALPHA-氰基-3-(乙氧羰基)-4H-1-苯并吡喃-4-乙酸乙酯 | 305834-79-1 |
| SCH-772984 | (R)-1-(2--2-氧(4-(4-(嘧啶-2-基)苯基)对二氮己环-1-基)乙基)-N-(3-(吡啶-4-基)-1H--5INDAZOL-基)吡咯烷-3-甲酰胺 | 942183-80-4 |
| Semaxinib(SU 5416) | SU5416 | 204005-46-9 |
| SGC-707 | N-6-异喹啉基-N'-[2-氧代-2-(1-吡咯烷基)乙基]脲 | 1687736-54-4 |
| SGI-7079 | 3-[2-[[3-氟-4-(4-甲基-1-哌嗪基)苯基]氨基]-5-甲基-7H-吡咯并[2,3-D]嘧啶-4-基]苯乙腈 | 1239875-86-5 |
| Sirtinol | 2-[[(2-羟基-1-萘基)亚甲基]氨基]-N-(1-苯基乙基)苯甲酰胺 | 410536-97-9 |
| SNS-032 | SNS-032 | 345627-80-7 |
| Spautin 1 | Spautin-1抑制剂 | 1262888-28-7 |
| SRT1720 HCl | SRT1720 | 1001645-58-4 |
| STF-31 | 4-((4-(叔丁基)苯基磺酰胺基)甲基)-N-(吡啶-3-基)苯甲酰胺 | 724741-75-7 |
| Suvorexant (MK-4305) | 苏沃雷生 | 1030377-33-3 |
| SW033291 | SW033291 | 459147-39-8 |
| SW-044248 | SW-044248 | 522650-83-5 |
| T-5224 | T-5224 | 530141-72-1 |
| T-705 | 法匹拉韦 | 259793-96-9 |
| TA-01 | TA 01 | 1784751-18-3 |
| TA-02 | TA 02 | 1784751-19-4 |
| TAK063 | 1-(2-氟-4-(1H-吡唑-1-基)苯基)-5-甲氧基-3-(1-苯基-1H-吡唑-5-基)哒嗪-4(1H)-酮 | 1238697-26-1 |
| TAK-117(INK1117,MLN1117) | [6-(2-氨基-5-苯并恶唑基)咪唑并[1,2-A]吡啶-3-基]-4-吗啉基甲酮 | 1268454-23-4 |
| TAS-301 | 3-(双(4-甲氧基苯基)亚甲基)吲哚啉-2-酮 | 193620-69-8 |
| Tasisulam(LY573636) | 他斯索兰 | 519055-62-0 |
| TC-O 9311 | TC-O 9311 | 444932-31-4 |
| TCS5861528 | N-(4-(仲丁基)苯基)-2-(1,3-二甲基-2,6-二氧代-2,3-二氢-1H-嘌呤-7(6H)-基)乙酰胺 | 332117-28-9 |
| TG-101209 | N-(1,1-二甲基乙基)-3-[[5-甲基-2-[[4-(4-甲基-1-哌嗪基)苯基]氨基]-4-嘧啶基]氨基]苯磺酰胺 | 936091-14-4 |
| TG6-10-1 | TG6-10-1 | 1415716-58-3 |
| TH287 | TH287 | 1609960-30-6 |
| Tideglusib(NP-031112) | 4-苄基-2-(萘-1-基)-[1,2,4]噻二唑烷-3,5-二酮 | 865854-05-3 |
| Tildipirosin | 泰地罗新 | 328898-40-4 |
| Tiplaxtinin(PAI-039) | 替普沙汀 | 393105-53-8 |
| Tirofiban | 替罗非班 | 144494-65-5 |
| TSU-68 | orantinib | 252916-29-3 |
| U0126 | 2,3-双[氨基[(2-氨基苯基)硫]亚甲基]丁二腈乙醇盐 | 1173097-76-1 |
| U-104 | U-104 | 178606-66-1 |
| UF010 | UF 010 | 537672-41-6 |
| UNC0321 (trifluoroacetate salt) | UNC0321 (trifluoroacetate salt) | |
| UNC2025 | 反式-4-[2-(丁基氨基)-5-[4-[(4-甲基-1-哌嗪基)甲基]苯基]-7H-吡咯并[2,3-D]嘧啶-7-基]-环己醇 | 1429881-91-3 |
| UPF1069 | 5-(2-氧代-2-苯基乙氧基)-1(2H)-异喹啉酮 | 1048371-03-4 |
| VE-821 | 3-氨基-6-[4-(甲基磺酰基)苯基]-N-苯基-2-吡嗪甲酰胺 | 1232410-49-9 |
| VR-23 | VR23 | 1624602-30-7 |
| VX-11e(TCS ERK 11e) | VX11E | 896720-20-0 |
| VX-661 | VX-661 | 1152311-62-0 |
| Walrycin B | WALRYCIN B | 878419-78-4 |
| WAY181187.HCl(WAY-181,187) | WAY 181187 | 554403-49-5 |
| WDR5-0103 | WDR5 0103 | 890190-22-4 |
| WHI-P131(Janex 1) | 4-(4'-羟基苯基)氨基-6,7-二甲氧基喹唑啉 | 202475-60-3 |
| WHI-P154 | 2-溴-4-(6,7-二甲氧基喹唑啉-4-基氨基)苯酚 | 211555-04-3 |
| WHI-P258 | WHI-P258 | 21561-09-1 |
| wp1066(STAT Inhibitor III) | (2E)-3-(6-溴-2-吡啶基)-2-氰基-N-[(1S)-1-苯基乙基]-2-丙烯酰胺 | 857064-38-1 |
| WY 14643 | 匹立尼酸 | 50892-23-4 |
| WZ-4002 | WZ4002 | 1213269-23-8 |
| XAV-939 | 3,5,7,8-四氢-2-[4-(三氟甲基)苯基]-4H-噻喃并[4,3-D]嘧啶-4-酮 | 284028-89-3 |
| XY-1 (Negative of SGC-707) | N-2-萘基-N'-[2-氧代-2-(1-吡咯烷基)乙基]脲 | 1624117-53-8 |
| YO-01027(Dibenzazepine) | 二苯并氮卓 | 209984-56-5 |
| ZM39923(HCL) | 3-[异丙基(苄基)氨基]-1-(2-萘基)-1-丙酮盐酸盐 | 1021868-92-7 |
| CHS-828 | N-[6-(4-氯苯氧基)己基]-N'-氰基-N''-4-吡啶基胍 | 200484-11-3 |
| RS-1 | 4-溴-N-(4-溴苯基)-3-[[(苯基甲基)氨基]磺酰基]苯甲酰胺 | 312756-74-4 |
